Headquartered in Avenue De La Grande Armee, Paris Fiscal year ends December NASDAQ: SNY sanofi.com
Sanofi is a global biopharmaceutical company. Its research and commercial focus is on three main areas: Immunology, Rare diseases and Vaccines, with selective activity in Neurology and Oncology.
Its largest product is Dupixent, co-developed and co-marketed with Regeneron under a profit-sharing alliance. Dupixent is approved in up to nine type 2 inflammatory indications, including atopic dermatitis, asthma, COPD and chronic spontaneous urticaria.
Rare disease medicines include:
- Hemophilia: ALTUVIIIO, Alprolix, Eloctate and Qfitlia
- Lysosomal storage disorders: Fabrazyme, Cerezyme, Cerdelga, Nexviazyme and Myozyme
- Ayvakit for systemic mastocytosis, gained through the Blueprint acquisition
- Cablivi, Xenpozyme and Wayrilz
Other medicines include:
- Oncology: Sarclisa and Jevtana
- Transplant: Rezurock and Thymoglobulin
- Type 1 diabetes: Tzield/Teizeild
- Insulins: Lantus and Toujeo
- Legacy cardiovascular brands: Plavix, Lovenox, Praluent, Aprovel and Multaq
The Vaccines business covers influenza and COVID-19 vaccines and pediatric polio/pertussis/hib combinations. It also includes Heplisav-B, from the Dynavax acquisition, the RSV antibody Beyfortus, and meningitis and travel vaccines such as MenQuadfi.
The US accounts for the majority of sales. Sanofi also distributes non-Sanofi vaccines through VaxServe.
Sanofi holds a 48.2% stake in Opella, its former consumer health business, through OPAL JV Co. It is reshaping its portfolio by transferring 20 mature medicines to Cheplapharm in exchange for a 26.4% equity stake. It has also expanded its Regeneron collaboration into next-generation long-acting antibodies.
The pipeline has 61 projects, including 36 potential new medicines and vaccines. Sanofi also tracks sustainability goals in healthcare access through its Global Health Unit and diabetes care programmes, as well as in environmental impact. Updated
Dupixent sales jumped 34.8% to $6.36 billion, beating expectations and lifting full-year guidance. Management is already spending the windfall, expanding the Regeneron alliance to protect earnings through Dupixent's eventual loss of exclusivity.
Sanofi cut a new 52-week low at $39.12, undercutting its October 5 floor and leaving the drugmaker without a bottom to lean on since last fall.
Sanofi set a new 52-week low at $40.67, taking out Monday's floor by 0.17% and leaving the $106 billion drugmaker at its weakest level in a year. Each new bottom this week has come by a sliver, so the next support test is the one to watch.
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has…
Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter. I think that…
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide…
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.
Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing. My tenure at these premier Wall Street firms exposed…
Investors have been running on a high for the last several months as all major U.S. indices have reached new record levels seemingly month after month. Sentiment on the stock market has…
It was nice while it lasted, and it may not be over, but the AI-driven stock market rally may run out of gas fast. While the Magnificent 7 has soared (the group…
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third…
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the country ages;…
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of…
Here are six European Dividend Aristocrats that are the most liquid and well-known for U.S. investors who are looking for income and a degree of diversification away from the American indexes.
For growth and income investors, adding top-quality dividend stocks based in Europe to domestic portfolios may be a solid way to go for the rest of the year. These five top European…
Sanofi is a global biopharmaceutical company. Its research and commercial focus is on three main areas: Immunology, Rare diseases and Vaccines, with selective activity in Neurology and Oncology.
24/7 Wall St.'s 12-month price target for SNY is $52.72, rated Buy. The Wall Street consensus target is $53.61. SNY price prediction →
